Publications by authors named "Ianni M"

Alzheimer's disease (AD), the leading cause of dementia, is a multifactorial disease influenced by aging, genetics, and environmental factors. miRNAs are crucial regulators of gene expression and play significant roles in AD onset and progression. This exploratory study analyzed the expression levels of 28 genes and 5 miRNAs (miR-124-3p, miR-125b-5p, miR-21-5p, miR-146a-5p, and miR-155-5p) related to AD pathology and neuroimmune responses using RT-qPCR.

View Article and Find Full Text PDF

New available drugs allow better control of systemic symptoms associated with myelofibrosis (MF) and splenomegaly but they do not modify the natural history of progressive and poor prognosis disease. Thus, hematopoietic stem cell transplantation (HSCT) is still considered the only available curative treatment for patients with MF. Despite the increasing number of procedures worldwide in recent years, HSCT for MF patients remains challenging.

View Article and Find Full Text PDF

The introduction of novel agents dramatically improved response and outcomes of multiple myeloma (MM) and led to a sharp decline in the use of allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Thus, recent guidelines do not recommend anymore allo-HSCT as consolidation in the first-line treatment of newly diagnosed MM, even in high-risk patients. In a relapsed/refractory setting, allo-HSCT is not routinely recommended but should only be performed within clinical trials in young and high-risk patients.

View Article and Find Full Text PDF
Article Synopsis
  • People with essential thrombocythemia (ET) usually take low-dose aspirin once a day to avoid blood clots, but this isn't always effective because their platelet levels change quickly.
  • A study tested if taking aspirin twice a day would work better and found that it did help lower certain blood markers and symptoms over 20 months.
  • The results showed that twice-daily aspirin caused fewer major blood clots, didn't lead to significant bleeding problems, and made patients feel better overall compared to taking it once a day.
View Article and Find Full Text PDF

Pancreatic cancer (PC) has a poor prognosis and displays resistance to immunotherapy. A better understanding of tumor-derived extracellular vesicle (EV) effects on immune responses might contribute to improved immunotherapy. EVs derived from Capan-2 and BxPC-3 PC cells isolated by ultracentrifugation were characterized by atomic force microscopy, Western blot (WB), nanoparticle tracking analysis, and label-free proteomics.

View Article and Find Full Text PDF

The treatment of acute myeloid leukemia (AML) with adverse genetics remains unsatisfactory, with very low response rates to standard chemotherapy and shorter durations of remission commonly observed in these patients. The complex biology of AML with adverse genetics is continuously evolving. Herein, we discuss recent advances in the field focusing on the contribution of molecular drivers of leukemia biogenesis and evolution and on the alterations of the immune system that can be exploited with immune-based therapeutic strategies.

View Article and Find Full Text PDF

Green technologies based on microwaves have been developed by the food industry to produce organoleptically acceptable fruit juices without preliminary processing. Microwave irradiation coupled with hydrodiffusion and gravity (MHG) combines microwave heating with the earth's gravity, allowing the collection of hydrophilic substances released from the irradiated matrix. To the best of our knowledge, MHG extraction has never been experimented to produce pomegranate juice.

View Article and Find Full Text PDF

GvHD still remains, despite the continuous improvement of transplantation platforms, a fearful complication of transplantation from allogeneic donors. Being able to separate GvHD from GvL represents the greatest challenge in the allogeneic transplant setting. This may be possible through continuous improvement of cell therapy techniques.

View Article and Find Full Text PDF
Article Synopsis
  • A study compared the effectiveness of standard-dose prednisone (PDN) and high-dose dexamethasone (HD-DXM) as first-line treatments for newly diagnosed primary immune thrombocytopenia (pITP) in adults aged 18-80.
  • The trial involved 113 patients, with 52% receiving PDN and 48% receiving HD-DXM, showing initial response rates of 78.57% for PDN versus 93.88% for HD-DXM; however, the long-term responses favored PDN.
  • Both treatments were well tolerated, with overall survival at 100% after 48 months, highlighting that while HD-DXM may yield quicker initial results, PDN offers more sustained
View Article and Find Full Text PDF
Article Synopsis
  • * The patient underwent a treatment regimen involving daratumumab, bortezomib, thalidomide, and dexamethasone, followed by stem-cell collection and autologous stem cell transplantation (ASCT).
  • * The combination treatment showed promising effectiveness for managing both cancers, with successful stem cell mobilization and quick recovery post-transplant, despite initial concerns regarding the management of these complex conditions.
View Article and Find Full Text PDF

CAR-T therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies. Patients who are receiving such therapy are susceptible to an increased incidence of infections due to post-treatment immunosuppression. The need for antifungal prophylaxis during the period of neutropenia remains to be determined.

View Article and Find Full Text PDF

The management of patients with acute myeloid leukemia (AML) relapsed post allogeneic hematopoietic stem cell transplantation (HSCT) remains a clinical challenge. Intensive treatment approaches are limited by severe toxicities in the early post-transplantation period. Therefore, hypomethylating agents (HMAs) have become the standard therapeutic approach due to favorable tolerability.

View Article and Find Full Text PDF

Background: Chronic lymphocytic leukemia (CLL) is an incurable disorder associated with alterations in several pathways essential for survival and proliferation. Despite the advances made in CLL therapy with the new target agents, in some cases, relapses and resistance could occur, making the discovery of new alternatives to manage CLL refractoriness necessary. To provide new therapeutic strategies for CLL, we investigated the anti-leukemic activity of silver nanoparticles (AgNPs), whose impact on CLL cells has been poorly explored.

View Article and Find Full Text PDF

Background: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a valid treatment for hematological oncological or metabolic diseases. Despite its therapeutic efficacy, it is an aggressive treatment that impacts negatively on quality of life (QoL) and may result in Post-Traumatic Stress Disorder (PTSD) symptoms. The aim of this study is to explore rates and risk factors for PTSD symptoms, and fatigue in post-HSCT patients with hematological malignancies.

View Article and Find Full Text PDF

Extracellular vesicles (EVs) are a heterogenous population of plasma membrane-surrounded particles that are released in the extracellular milieu by almost all types of living cells. EVs are key players in intercellular crosstalk, both locally and systemically, given that they deliver their cargoes (consisting of proteins, lipids, mRNAs, miRNAs, and DNA fragments) to target cells, crossing biological barriers. Those mechanisms further trigger a wide range of biological responses.

View Article and Find Full Text PDF

We are recently faced with a progressive evolution of the therapeutic paradigm for radioiodine refractory differentiated thyroid cancer (RAI-R DTC), since the advent of tissue agnostic inhibitors. Thus, tumor genotype assessment is always more relevant and is playing a crucial role into clinical practice. We report the case of an elderly patient with advanced papillary thyroid carcinoma (PTC) harboring fusion with four co-occurring mutations involving , , and mutations, treated with pralsetinib under a compassionate use program.

View Article and Find Full Text PDF

Donor lymphocyte infusion (DLI) is a treatment option to prevent or treat relapse after allogeneic hematopoietic cell transplantation (HCT). We here report data for 173 patients who received one or multiple DLIs after haploidentical-HCT with post-transplant cyclophosphamide (PTCY) at 47 EBMT centers from 2009 to 2018. Indication for DLI was: prophylactic for 59 (34.

View Article and Find Full Text PDF

NOTCH1 alterations have been associated with chronic lymphocytic leukemia (CLL), but the molecular mechanisms underlying NOTCH1 activation in CLL cells are not completely understood. Here, we show that GSK3β downregulates the constitutive levels of the active NOTCH1 intracellular domain (N1-ICD) in CLL cells. Indeed, GSK3β silencing by small interfering RNA increases N1-ICD levels, whereas expression of an active GSK3β mutant reduces them.

View Article and Find Full Text PDF
Article Synopsis
  • - Essential thrombocythemia (ET) is a blood disorder that leads to an increase in platelet production and can cause complications like blood clots; standard low-dose aspirin does not adequately inhibit platelet function in these patients.
  • - The ARES trial investigated the effectiveness of varying doses of aspirin and found that the platelet count and cytoreductive treatment (which lowers platelet levels) significantly influence how well aspirin works in ET patients, with notable differences between those on and off cytoreductive drugs.
  • - Ultimately, more frequent dosing of aspirin (twice or three times daily) improves platelet inhibition and minimizes response variability among patients, regardless of whether they are undergoing cytoreductive treatment or not.
View Article and Find Full Text PDF